Group 1 - The core viewpoint of the news is that Ruimait has experienced a decline in stock price, with a cumulative drop of 6.36% over four consecutive days, currently trading at 85.52 yuan per share [1] - Ruimait Medical Technology Co., Ltd. specializes in the research, production, and sales of medical devices and consumables in the respiratory health field, primarily serving patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The company's main business revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - According to data, Nord Fund holds a significant position in Ruimait, with its Nord Small and Mid-Cap Mixed Fund (570006) owning 18,000 shares, accounting for 5.02% of the fund's net value [2] - The fund has incurred a floating loss of approximately 10.46 million yuan during the four-day decline [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a return of 45% year-to-date, ranking 1247 out of 8244 in its category [2]
瑞迈特股价连续4天下跌累计跌幅6.36%，诺德基金旗下1只基金持1.8万股，浮亏损失10.46万元